About Armadillo repeat-containing X-linked protein 1
Armadillo repeat-containing X-linked protein 1 (ARMCX1) is a protein
from Homo sapiens identified by UniProt accession
Q9P291, 453 residues long.
MolForge cross-references it against 0 known binders and
46 disease associations.
Target properties
| Protein name | Armadillo repeat-containing X-linked protein 1 |
| UniProt accession | Q9P291 |
| Gene | ARMCX1 |
| Organism | Homo sapiens |
| Length | 453 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (46)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.05
- gonorrhea · score 0.05
- Hepatic veno-occlusive disease - immunodeficiency · score 0.05
- immunodeficiency 75 · score 0.03
- ovarian carcinoma · score 0.03
- endometrial carcinoma · score 0.01
- lung carcinoma · score 0.01
- colorectal cancer · score 0.01
- cancer · score 0.01
- prostate carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9P291-F1 | alphafold | PREDICTED | 72.63 | — |
Amino-acid sequence (453 residues)
MGRTREAGCV AAGVVIGAGA CYCVYRLAWG RDENEKIWDE DEESTDTSEI GVETVKGAKT NAGAGSGAKL QGDSEVKPEV SLGLEDCPGV KEKAHSGSHS GGGLEAKAKA LFNTLKEQAS AKAGKGARVG TISGNRTLAP SLPCPGGRGG GCHPTRSGSR AGGRASGKSK GKARSKSTRA PATTWPVRRG KFNFPYKIDD ILSAPDLQKV LNILERTNDP FIQEVALVTL GNNAAYSFNQ NAIRELGGVP IIAKLIKTKD PIIREKTYNA LNNLSVNAEN QGKIKTYISQ VCDDTMVCRL DSAVQMAGLR LLTNMTVTNH YQHLLSYSFP DFFALLFLGN HFTKIQIMKL IINFTENPAM TRELVSCKVP SELISLFNKE WDREILLNIL TLFENINDNI KNEGLASSRK EFSRSSLFFL FKESGVCVKK IKALANHNDL VVKVKVLKVL TKL
Explore Armadillo repeat-containing X-linked protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets